On April 21, 2026 Dewpoint Therapeutics Inc., a clinical-state biotechnology company pioneering condensate therapeutics, reported new preclinical data at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 highlighting its approach to targeting MYC-driven cancers through biomolecular condensate modulation.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The data, presented by Ann Boija, SVP and Head of Research, describe Dewpoint’s orally bioavailable MYC development candidate, designed to disrupt transcriptional condensates associated with MYC activity. MYC is one of the most pervasive drivers of cancer but has historically remained beyond the reach of conventional drug discovery approaches. Dewpoint’s strategy directly targets the cellular context required for MYC function, representing a differentiated approach to modulating this high-value oncogenic driver.
In preclinical models, Dewpoint’s candidate reduced MYC condensates and modulated MYC-dependent gene expression, resulting in inhibition of MYC-driven cancer cell growth. The compound demonstrated anti-tumor activity, including tumor regression and stasis in solid tumor models following oral administration, along with a favorable tolerability profile supporting further development.
"MYC has remained out of reach for decades," said Boija. "These data establish a new path to targeting key oncogenic transcription factors such as MYC, overcoming longstanding limitations in the field. We see strong potential for this approach to translate into meaningful therapeutic impact for patients."
Dewpoint’s condensate-based drug discovery approach is designed to address high-value targets that have proven difficult to drug using conventional approaches, including a β-catenin program in clinical development and additional oncogenic transcription factor programs in earlier stages.
"We believe condensate biology defines a new frontier for drug discovery," said Isaac Klein, Chief Scientific Officer of Dewpoint Therapeutics. "By targeting the organizational principles of the cell, we can systematically access disease-driving mechanisms that have historically been beyond reach."
MYC dysregulation is implicated across a wide range of cancers and remains a major area of unmet medical need.
(Press release, Dewpoint Therapeutics, APR 21, 2026, View Source [SID1234664668])